Press Releases

Date Title and Summary
Toggle Summary Accuray Educates Radiation Oncology Practices on the Potential Impact of the Proposed Alternative Payment Model (RO-APM)
SUNNYVALE, Calif. , Sept. 19, 2019 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) today published an informational guide designed to help radiation oncology practices understand the complexities of the much-anticipated proposed Medicare & Medicaid reimbursement changes.
Toggle Summary Accuray To Report Fiscal 2020 First Quarter Financial Results on October 29, 2019
  SUNNYVALE, Calif. , Oct. 10, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2019 on Tuesday, October 29, 2019 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT / 4:30 p.m.
Toggle Summary Accuray Appoints Medtech Veteran Suzanne Winter as Chief Commercial Officer
SUNNYVALE, Calif. , Oct. 21, 2019 /PRNewswire/ --  Accuray Incorporated (Nasdaq: ARAY) announced today that Suzanne Winter has joined the company as Senior Vice President, Chief Commercial Officer effective October 21, 2019 . Ms. Winter will have global responsibility for the commercial function
Toggle Summary First Asia-Pacific hospital treats patients with RayStation and Radixact
SUNNYVALE, Calif. , Oct. 28, 2019 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) – Thailand's Lopburi Cancer Hospital , a center of excellence for cancer treatment, is the first in the Asia-Pacific region to clinically use the combination of RaySearch's treatment planning system RayStation®
Toggle Summary Accuray Reports Fiscal 2020 First Quarter Financial Results
SUNNYVALE, Calif. , Oct. 29, 2019 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2020 ended September 30, 2019 . Recent Company Highlights Gross orders increased 28 percent year over year to $78.5 million 11 orders received
Toggle Summary Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules
SUNNYVALE, Calif. , Nov. 6, 2019 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Suzanne Winter , the company's new Senior Vice President, Chief Commercial Officer.  As a material inducement to Ms.
Toggle Summary Stanford University Medical Center to Acquire Second Accuray CyberKnife® M6™ System
New System will be Used to Treat Diseases in the Brain and Base of the Skull SUNNYVALE, Calif. , Dec. 4, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Stanford University Medical Center has selected a second CyberKnife ® M6™ System to expand access to precise
Toggle Summary Timpanogos Cancer Services First in Utah to Offer Precise and Accurate Radiation Treatments with the Accuray Radixact® System
System is Designed to Improve Treatment Results, Minimize Treatment Impact on Patients' Quality of Life SUNNYVALE, Calif. , Dec. 12, 2019 /PRNewswire/ -- Timpanogos Cancer Services made history in Utah recently with the installation of the state's first Radixact ® System , the next-generation
Toggle Summary Accuray to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 15, 2020
SUNNYVALE, Calif. , Jan. 6, 2020 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that Joshua H. Levine , president and chief executive officer, will present at the 38 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 10:00 a.m. PT .
Toggle Summary Accuray CyberKnife® System Provides Excellent Disease Control for Men with Recurrent Prostate Cancer, a Medical Condition with Few Viable Treatment Options
SUNNYVALE, Calif. , Jan. 8, 2020 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today data from a prospective study which showed that at five years, stereotactic body radiation therapy (SBRT) administered with the CyberKnife ® System provided excellent disease control with low rates

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.